1)FDA says the implant is fast track and approved stock price will rapidly rise.
2)FDA gives guidance and provides a path to approval of the implant stock price will rise at a slower pace.
3) FDA denies going forward on the implant Biocorrx will continue adding clinics using the implant off label. Stock price will fluctuate but down the road stock price be higher than today.
Based on the fact that the implant has already established a proven track record of being effective and safe at the minimum IMHO expect number 2 scenario but wouldn't be surprise if number one was the outcome.
What can not be over stated, a judge in OHIO has order a man to take a treatment that is not approved by FDA for what it was approved for.
Meaning the state of OHIO has given its stamp of approval that the product is safe and effective. Powerful recommendation going into an FDA meeting. JMHO